Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2023)

Inhibikase Therapeutics (IKT) posted quarterly Non-Current Debt of $381784.0 for Q4 2023, up 53.38% quarter-over-quarter from $248911.0 in Q3 2021.

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2023) Analysis & Trends

Inhibikase Therapeutics (IKT) has reported Non-Current Debt for 3 consecutive years, with $381784.0 the latest figure, recorded in Q4 2023.

In Q4 2023, Non-Current Debt changed N/A year-over-year to $381784.0; the TTM figure through Dec 2023 stood at $381784.0 (changed N/A YoY), while the FY2023 annual figure was $381784.0, changed N/A from the prior year.
Non-Current Debt improved to $381784.0 in Q4 2023 per IKT's latest filing, from $248911.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $1.2 million in Q1 2021 and bottomed at $248911.0 in Q2 2021.
Historically, Non-Current Debt has averaged $479953.4 across 3 years, with a median of $276461.0 in 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Inhibikase Therapeutics	420.72 Mn	261.70 Mn	-	-

Download Data